You are here: Industry Insights > Kisqali

News List

NICE recommends routine funding for Novartis’ Kisqali pharmatimes
March 01, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.
Novartis’ Kisqali demonstrates nearly five years median OS in metastatic breast cancer pharmaceutical-business-review
December 14, 2020
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal ...
Kisqali Shows Overall Survival Benefit in HR+/HER2- advanced breast cancer americanpharmaceuticalreview
June 02, 2020
Kisqali Shows Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer.
New analysis shows survival benefit of Novartis' Kisqali pharmatimes
May 28, 2020
Novartis says a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials reinforce the overall survival (OS) benefit of Kisqali (ribociclib) in breast cancer.
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial pharmatimes
June 03, 2019
The overall survival results were presented as a late-breaker at the 2019 ASCO Annual Meeting and will be published in The New England Journal of Medicine.
Newer Drug Extends Lives of Young Breast Cancer Patients drugs
June 03, 2019
Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found.
Kisqali receives breakthrough therapy designation for advanced breast cancer europeanpharmaceuticalreview
April 30, 2019
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer…
A slowing market—not new rivals—is hurting Pfizer's star cancer drug Ibrance, executives say pfizer
August 02, 2018
Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because new rivals are stealing its share.
Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali fiercepharma
July 27, 2018
Less than one day after Novartis CEO Vas Narasimhan talked up a potential key approval for lagging breast cancer drug Kisqali, the company has that approval in hand.
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it? fiercepharma
June 04, 2018
Novartis rolled out positive first-line metastatic Kisqali results at annual ASCO meeting in Chicago.

Previous page 1 2 Next page